Drug Interaction Report
6 potential interactions and/or warnings found for the following 2 drugs:
- ezetimibe / rosuvastatin
- deutivacaftor / tezacaftor / vanzacaftor
Interactions between your drugs
ezetimibe rosuvastatin
Applies to: ezetimibe / rosuvastatin, ezetimibe / rosuvastatin
Using ezetimibe together with rosuvastatin can increase the risk of side effects such as liver damage and a rare but serious condition called rhabdomyolysis that involves the breakdown of skeletal muscle tissue. In some cases, rhabdomyolysis can cause kidney damage and even death. You may need a dose adjustment or more frequent monitoring by your doctor to safely use both medications. Let your doctor know immediately if you have unexplained muscle pain, tenderness, or weakness while taking these medications, especially if these symptoms are accompanied by fever or dark colored urine. You should also seek immediate medical attention if you develop fever, chills, joint pain or swelling, unusual bleeding or bruising, skin rash, itching, loss of appetite, fatigue, nausea, vomiting, dark colored urine, and/or yellowing of the skin or eyes, as these may be signs and symptoms of liver damage. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
rosuvastatin vanzacaftor
Applies to: ezetimibe / rosuvastatin, deutivacaftor / tezacaftor / vanzacaftor
Consumer information for this interaction is not currently available.
MONITOR: Coadministration with vanzacaftor and/or deutivacaftor, both in vitro inhibitors of the breast cancer resistance protein (BCRP), may increase the plasma concentrations and pharmacologic effects of sensitive BCRP substrates. The proposed mechanism involves decreased clearance due to inhibition of BCRP by vanzacaftor and/or deutivacaftor. However, this interaction has not been studied clinically.
MANAGEMENT: Caution is advised when vanzacaftor and/or deutivacaftor are used concomitantly with drugs that are sensitive substrates of the BCRP transporter. Monitoring for signs and symptoms of increased exposure to the BCRP substrate should be considered whenever vanzacaftor and/or deutivacaftor are added to or withdrawn from therapy. The prescribing information for concomitant medications may be consulted to assess the benefits versus risks of coadministration, as well as any dosage adjustments that may be required during coadministration and/or following the discontinuation of the BCRP inhibitor.
rosuvastatin deutivacaftor
Applies to: ezetimibe / rosuvastatin, deutivacaftor / tezacaftor / vanzacaftor
Consumer information for this interaction is not currently available.
MONITOR: Coadministration with vanzacaftor and/or deutivacaftor, both in vitro inhibitors of the breast cancer resistance protein (BCRP), may increase the plasma concentrations and pharmacologic effects of sensitive BCRP substrates. The proposed mechanism involves decreased clearance due to inhibition of BCRP by vanzacaftor and/or deutivacaftor. However, this interaction has not been studied clinically.
MANAGEMENT: Caution is advised when vanzacaftor and/or deutivacaftor are used concomitantly with drugs that are sensitive substrates of the BCRP transporter. Monitoring for signs and symptoms of increased exposure to the BCRP substrate should be considered whenever vanzacaftor and/or deutivacaftor are added to or withdrawn from therapy. The prescribing information for concomitant medications may be consulted to assess the benefits versus risks of coadministration, as well as any dosage adjustments that may be required during coadministration and/or following the discontinuation of the BCRP inhibitor.
Drug and food interactions
tezacaftor food
Applies to: deutivacaftor / tezacaftor / vanzacaftor
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of tezacaftor, deutivacaftor, and vanzacaftor. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. In general, the effect of grapefruit juice is concentration-, dose- and preparation- dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. The risk and/or severity of serious side effects such as liver damage may be increased.
ADJUST DOSING INTERVAL: Administration with fat-containing food may increase the oral bioavailability of vanzacaftor and deutivacaftor. Administration with a fat containing meal increased vanzacaftor systemic exposure (AUC) by 4- (low-fat meal) to 6- (high-fat meal) fold. While deutivacaftor AUC increased approximately 3- (low-fat meal) to 4- (high-fat meal) fold, relative to administration in a fasting state. Tezacaftor exposure is not significantly affected by administration of fat-containing foods.
MANAGEMENT: Patients treated with tezacaftor, deutivacaftor, vanzacaftor -containing medications should avoid consumption of grapefruit juice and any food that contains grapefruit. To improve absorption, patients should be advised to take vanzacaftor and/or deutivacaftor containing medications with fat-containing foods such as eggs, avocados, nuts, meat, butter, peanut butter, cheese pizza, and whole-milk dairy products at approximately the same time of the day. A typical cystic fibrosis diet will satisfy this requirement.
vanzacaftor food
Applies to: deutivacaftor / tezacaftor / vanzacaftor
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of tezacaftor, deutivacaftor, and vanzacaftor. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. In general, the effect of grapefruit juice is concentration-, dose- and preparation- dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. The risk and/or severity of serious side effects such as liver damage may be increased.
ADJUST DOSING INTERVAL: Administration with fat-containing food may increase the oral bioavailability of vanzacaftor and deutivacaftor. Administration with a fat containing meal increased vanzacaftor systemic exposure (AUC) by 4- (low-fat meal) to 6- (high-fat meal) fold. While deutivacaftor AUC increased approximately 3- (low-fat meal) to 4- (high-fat meal) fold, relative to administration in a fasting state. Tezacaftor exposure is not significantly affected by administration of fat-containing foods.
MANAGEMENT: Patients treated with tezacaftor, deutivacaftor, vanzacaftor -containing medications should avoid consumption of grapefruit juice and any food that contains grapefruit. To improve absorption, patients should be advised to take vanzacaftor and/or deutivacaftor containing medications with fat-containing foods such as eggs, avocados, nuts, meat, butter, peanut butter, cheese pizza, and whole-milk dairy products at approximately the same time of the day. A typical cystic fibrosis diet will satisfy this requirement.
deutivacaftor food
Applies to: deutivacaftor / tezacaftor / vanzacaftor
Consumer information for this interaction is not currently available.
GENERALLY AVOID: Grapefruit juice may increase the plasma concentrations of tezacaftor, deutivacaftor, and vanzacaftor. The proposed mechanism is inhibition of CYP450 3A4-mediated first-pass metabolism in the gut wall by certain compounds present in grapefruit. In general, the effect of grapefruit juice is concentration-, dose- and preparation- dependent, and can vary widely among brands. Certain preparations of grapefruit juice (e.g., high dose, double strength) have sometimes demonstrated potent inhibition of CYP450 3A4, while other preparations (e.g., low dose, single strength) have typically demonstrated moderate inhibition. The risk and/or severity of serious side effects such as liver damage may be increased.
ADJUST DOSING INTERVAL: Administration with fat-containing food may increase the oral bioavailability of vanzacaftor and deutivacaftor. Administration with a fat containing meal increased vanzacaftor systemic exposure (AUC) by 4- (low-fat meal) to 6- (high-fat meal) fold. While deutivacaftor AUC increased approximately 3- (low-fat meal) to 4- (high-fat meal) fold, relative to administration in a fasting state. Tezacaftor exposure is not significantly affected by administration of fat-containing foods.
MANAGEMENT: Patients treated with tezacaftor, deutivacaftor, vanzacaftor -containing medications should avoid consumption of grapefruit juice and any food that contains grapefruit. To improve absorption, patients should be advised to take vanzacaftor and/or deutivacaftor containing medications with fat-containing foods such as eggs, avocados, nuts, meat, butter, peanut butter, cheese pizza, and whole-milk dairy products at approximately the same time of the day. A typical cystic fibrosis diet will satisfy this requirement.
Therapeutic duplication warnings
No duplication warnings were found for your selected drugs.
Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.
Drug Interaction Classification
| Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit. | |
| Moderately clinically significant. Usually avoid combinations; use it only under special circumstances. | |
| Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan. | |
| No interaction information available. |
See also:
Leqvio
Leqvio is used in adults with primary hyperlipidemia to reduce low-density lipoprotein (LDL-C) ...
Repatha
Repatha (evolocumab) is a PCSK9 inhibitor used to lower high cholesterol alongside dietary changes ...
Ozempic
Learn about Ozempic (semaglutide) for type 2 diabetes treatment, weight management, cardiovascular ...
Lipitor
Lipitor is used to treat high cholesterol. Learn about side effects, interactions and indications.
Crestor
Crestor (rosuvastatin) is used to treat high cholesterol and high triglycerides in the blood ...
Zetia
Zetia (ezetimibe) is used to treat high cholesterol. Includes Zetia side effects, interactions and ...
Zocor
Zocor (simvastatin) reduces low-density lipoprotein cholesterol and total cholesterol in the blood ...
Praluent
Praluent (alirocumab) is an injectable medicine that is given under your skin which may be used in ...
Mevacor
Mevacor is used for high cholesterol, high cholesterol, familial heterozygous ...
Learn more
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
Check Interactions
To view an interaction report containing 4 (or more) medications, please sign in or create an account.
Save Interactions List
Sign in to your account to save this drug interaction list.